In the past several years, there has been much controversy surrounding the possible link between a class of Hepatitis C drugs known as direct-acting antivirals (DAAs) and hepatocellular carcinoma (HCC), or liver cancer.  The DAA drugs include Harvoni, Sovaldi, Viekira Pak, Technivie, Olysio, Daklinza, Epclusa, and Zepatier. In July, I wrote an … [Read more...]